Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CVS HEALTH CorpCVS · Entity 2884 | EVP & Chief Financial Officer | April 01, 2023 | April 04, 2023 |
| DAVITA INC.DVA · Entity 3482 | Director | May 15, 2021 | May 19, 2021 |
| Evolent Health, Inc.EVH · Entity 5492 | Director | June 04, 2026 | June 08, 2026 |
| TRINET GROUP, INC.TNET · Entity 4202 | Director | March 24, 2021 | March 26, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CVS HEALTH Corp
Report date April 01, 2023 · Filed April 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $74.31 · Expires 2033-04-01 | Direct | 148,456 |
Reported balance
After 2023-04-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-04-01 · Grant · Acquired 148,456 · Balance 148,456 F2: Option becomes exercisable in four equal annual installments, commencing 4/1/2024. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2031-05-28 | Direct | 97,562 |
Reported balance
Holding disclosure · report date 2023-04-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 97,562 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $101.09 · Expires 2032-04-01 | Direct | 103,950 |
Reported balance
Holding disclosure · report date 2023-04-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 103,950 F1: Option became exercisable in four equal installments, commencing 4/1/2023. |
| Common StockSEC Table I · non-derivative | Direct | 9,260 |
Reported balance
Holding disclosure · report date 2023-04-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 9,260 |
| Common Stock (Restricted)SEC Table I · non-derivative | Direct | 34,706 |
Reported balance
Holding disclosure · report date 2023-04-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 34,706 |
Filing footnotes · ownership attribution and instrument terms
F1: Option became exercisable in four equal installments, commencing 4/1/2023.
F2: Option becomes exercisable in four equal annual installments, commencing 4/1/2024.
DAVITA INC.
Report date May 15, 2021 · Filed May 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,105 |
Reported balance
After 2021-05-15 transaction · row 1
1 source rowRow 1 · 2021-05-15 · Grant · Acquired 379 · Balance 1,105 |
Evolent Health, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 63,075 |
Reported balance
After 2026-06-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 41,096 · Balance 63,075 F1: Represents restricted stock units granted to Mr. Guertin pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2: Securities vest on the earlier of June 4, 2027, and the date of the Company's 2027 annual meeting, subject to the reporting person's continued service on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted to Mr. Guertin pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
F2: Securities vest on the earlier of June 4, 2027, and the date of the Company's 2027 annual meeting, subject to the reporting person's continued service on the vesting date.
TRINET GROUP, INC.
Report date March 24, 2021 · Filed March 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,560 |
Reported balance
After 2021-03-24 transaction · row 1
1 source rowRow 1 · 2021-03-24 · Grant · Acquired 2,576 · Balance 8,560 F1: Reflects the grant of Restricted Stock Units that convert into Common Stock, par value $0.000025 per share, of the Issuer, on a one-for-one basis. The Restricted Stock Units will vest 100% on the date of the Company's 2022 Annual Meeting of the Stockholders, subject to the director's continued service. The Restricted Stock Units are also subject to accelerated vesting upon certain events. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of Restricted Stock Units that convert into Common Stock, par value $0.000025 per share, of the Issuer, on a one-for-one basis. The Restricted Stock Units will vest 100% on the date of the Company's 2022 Annual Meeting of the Stockholders, subject to the director's continued service. The Restricted Stock Units are also subject to accelerated vesting upon certain events.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AETNA INC /PA/
Report date November 28, 2018 · Filed November 28, 2018
Section 16 reporting ended · disclosed 2018-11-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-11-28 transaction · row 1
1 source rowRow 1 · 2018-11-28 · Disposition to issuer · Disposed 11,058 · Balance 0 F1: Converted pursuant to the merger agreement (the "Merger Agreement") between CVS Health Corporation ("CVS Health") and Aetna Inc. ("Aetna") into $145 in cash and 0.8378 shares of CVS Health Common Stock for each share of Aetna Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectBy 2018 GRAT | 0 |
Reported balance
After 2018-11-28 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-11-28 · Disposition to issuer · Disposed 11,174 · Balance 0 F1: Converted pursuant to the merger agreement (the "Merger Agreement") between CVS Health Corporation ("CVS Health") and Aetna Inc. ("Aetna") into $145 in cash and 0.8378 shares of CVS Health Common Stock for each share of Aetna Common Stock. F2: Represents shares held in 2018 Grantor Retained Annuity Trust ("GRAT") for which the Reporting Person is sole trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy 2018 CRUT | 0 |
Reported balance
After 2018-11-28 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2018-11-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Converted pursuant to the merger agreement (the "Merger Agreement") between CVS Health Corporation ("CVS Health") and Aetna Inc. ("Aetna") into $145 in cash and 0.8378 shares of CVS Health Common Stock for each share of Aetna Common Stock. F3: Represents shares held in 2018 Charitable Remainder Unitrust ("CRUT") for which the Reporting Person is sole trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 0 |
Reported balance
After 2018-11-28 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2018-11-28 · Disposition to issuer · Disposed 634.7406 · Balance 0 F1: Converted pursuant to the merger agreement (the "Merger Agreement") between CVS Health Corporation ("CVS Health") and Aetna Inc. ("Aetna") into $145 in cash and 0.8378 shares of CVS Health Common Stock for each share of Aetna Common Stock. F4: Represents the pro rata portion of the stock portion of the Aetna Common Stock Fund held by Reporting Person on October 31, 2018 pursuant to the Aetna Inc. 401(k) Plan. The information is based on information provided by the Plan Trustee as of that date. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $100.50 | Direct | 0 |
Reported balance
After 2018-11-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-11-28 · Disposition to issuer · Disposed 25,715 · Balance 0 F5: Represents Stock Appreciation Rights ("SARs") granted under the Aetna Inc. 2010 Stock Incentive Plan (the "Plan") on March 2, 2015. These SARs were canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash for each SAR equal to (a) $145 plus (b) 0.8378 multiplied by the average of the volume weighted averages of the trading prices of CVS Health Common Stock on each of the five consecutive trading days ending on the trading day two trading days prior to the closing date, less (c) the exercise price (the "SAR Amount"). |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $116.44 | Direct | 0 |
Reported balance
After 2018-11-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-11-28 · Disposition to issuer · Disposed 11,415 · Balance 0 F6: Represents SARs granted under the Plan on September 24, 2015. These SARs were canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash for each SAR equal to the SAR Amount. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $103.45 | Direct | 0 |
Reported balance
After 2018-11-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-11-28 · Disposition to issuer · Disposed 55,376 · Balance 0 F7: Represents SARs granted under the Plan on February 19, 2016. Of this amount, 50% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash equal to the SAR Amount. Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $125.27 | Direct | 0 |
Reported balance
After 2018-11-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-11-28 · Disposition to issuer · Disposed 81,864 · Balance 0 F8: Represents SARs granted under the Plan on February 17, 2017, of which 33.3% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash for each SAR equal to the SAR Amount. Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-11-28 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-11-28 · Disposition to issuer · Disposed 23,780 · Balance 0 F9: Represents Performance Stock Units ("PSUs") earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on February 19, 2016. These PSUs were converted to time-vesting CVS Health Restricted Stock Units ("RSUs") pursuant to the terms of the Merger Agreement. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-11-28 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-11-28 · Disposition to issuer · Disposed 10,179 · Balance 0 F10: PSUs earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on February 17, 2017. These PSUs were converted to time-vesting CVS Health RSUs pursuant to the terms of the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-11-28 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-11-28 · Disposition to issuer · Disposed 23,940 · Balance 0 F11: RSUs under the Plan granted on March 2, 2018. These RSUs were converted to CVS Health RSUs pursuant to the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Converted pursuant to the merger agreement (the "Merger Agreement") between CVS Health Corporation ("CVS Health") and Aetna Inc. ("Aetna") into $145 in cash and 0.8378 shares of CVS Health Common Stock for each share of Aetna Common Stock.
F2: Represents shares held in 2018 Grantor Retained Annuity Trust ("GRAT") for which the Reporting Person is sole trustee.
F3: Represents shares held in 2018 Charitable Remainder Unitrust ("CRUT") for which the Reporting Person is sole trustee.
F4: Represents the pro rata portion of the stock portion of the Aetna Common Stock Fund held by Reporting Person on October 31, 2018 pursuant to the Aetna Inc. 401(k) Plan. The information is based on information provided by the Plan Trustee as of that date.
F5: Represents Stock Appreciation Rights ("SARs") granted under the Aetna Inc. 2010 Stock Incentive Plan (the "Plan") on March 2, 2015. These SARs were canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash for each SAR equal to (a) $145 plus (b) 0.8378 multiplied by the average of the volume weighted averages of the trading prices of CVS Health Common Stock on each of the five consecutive trading days ending on the trading day two trading days prior to the closing date, less (c) the exercise price (the "SAR Amount").
F6: Represents SARs granted under the Plan on September 24, 2015. These SARs were canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash for each SAR equal to the SAR Amount.
F7: Represents SARs granted under the Plan on February 19, 2016. Of this amount, 50% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash equal to the SAR Amount. Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement.
F8: Represents SARs granted under the Plan on February 17, 2017, of which 33.3% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash for each SAR equal to the SAR Amount. Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement.
F9: Represents Performance Stock Units ("PSUs") earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on February 19, 2016. These PSUs were converted to time-vesting CVS Health Restricted Stock Units ("RSUs") pursuant to the terms of the Merger Agreement.
F10: PSUs earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on February 17, 2017. These PSUs were converted to time-vesting CVS Health RSUs pursuant to the terms of the Merger Agreement.
F11: RSUs under the Plan granted on March 2, 2018. These RSUs were converted to CVS Health RSUs pursuant to the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2017 Filed Feb 22, 2017 16:27 UTC | AETNA INC /PA/ AET · Entity 107289 | GrantStock Appreciation Rights · Derivative | 81,864 | $125.27 Strike: $125.27 | $10,255,103.28 |
DisclosureSEC source: 0001231553-17-000002 · edgar.xml · derivative · entry 1 GUERTIN SHAWN M · CIK 0001231553 · Exec. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,864 Underlying: Common Stock · 81,864 shares Expires 2027-02-17 F1 · derivative.exercise_date: Stock Appreciation Rights granted under the Aetna Inc. 2010 Stock Incentive Plan, exercisable in three annual installments beginning February 17, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.